The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized placebo-controlled phase III study of duloxetine for treatment of aromatase inhibitor (AI)-associated musculoskeletal symptoms in women with early-stage breast cancer: SWOG S1202.
N. Lynn Henry
No relevant relationships to disclose
Joseph M. Unger
No relevant relationships to disclose
Anne Schott
No relevant relationships to disclose
Lisa Hansen
No relevant relationships to disclose
Danika Lew
No relevant relationships to disclose
James Lloyd Wade
No relevant relationships to disclose
Carol Moinpour
No relevant relationships to disclose
Gabriel N. Hortobagyi
No relevant relationships to disclose
Frank L. Meyskens
No relevant relationships to disclose